Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | HTR1E | P28566 | 1/20 | 0.57 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5369238 | 0.97 | NPSR1 (0.53) | NPSR1MAPTHTR1ES1PR3MEN1 | |
| SCHEMBL5366626 | 0.93 | ALDH1A1 (0.52) | NPSR1MAPTHTR1ES1PR3MEN1 | |
| SCHEMBL3900070 | 0.85 | AKR1C1 (0.59) | NPSR1MAPTHTR1ES1PR3MEN1 | |
| SCHEMBL2815457 | 0.83 | NPSR1 (0.57) | NPSR1MAPTHTR1ES1PR3MEN1 | |
| SCHEMBL3224174 | 0.81 | NPSR1 (0.55) | NPSR1MAPTHTR1ES1PR3MEN1 | |
| SCHEMBL17109512 | 0.80 | NPSR1 (0.53) | NPSR1MAPTHTR1ES1PR3MEN1 | |
| SCHEMBL8097387 | 0.78 | ALDH1A1 (0.50) | NPSR1MAPTMEN1CYP1A2CYP2C19 | |
| SCHEMBL1769201 | 0.77 | NPSR1 (0.50) | NPSR1MAPTHTR1ES1PR3MEN1 | |
| SCHEMBL1627734 | 0.77 | HDAC4 (0.66) | NPSR1MAPTLMNAALDH1A1HDAC1 | |
| SCHEMBL3227451 | 0.76 | MEN1 (0.58) | NPSR1MAPTHTR1ES1PR3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166616-B2 | Substituted alkanoic acids | AVENTIS PHARMA LIMITED (GB) | 2007-01-23 | — | — | US | disclosed |
| US-20040006056-A1 | For therapy of disease states capable of being modulated by the inhibition of cell adhesion; therapy of asthma | AVENTIS PHARMA LIMITED (GB) | 2004-01-08 | — | — | US | disclosed |
| EP-1330432-A2 | SUBSTITUTED ALKANOIC ACIDS | Aventis Pharma Limited (GB) | 2003-07-30 | — | — | EP | disclosed |
| WO-2002036553-A2 | SUBSTITUTED ALKANOIC ACIDS | AVENTIS PHARMA LIMITED (GB) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006056-A1 | For therapy of disease states capable of being modulated by the inhibition of cell adhesion; therapy of asthma | VCAM1, LTB4R, ITGA1 | NPSR1 175/4885MAPT 4800/4885HTR1E 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.